_edited.png)
Opponents Appeal Medicare Hemp CBD Plan
Fast Facts
Who / Where: Smart Approaches to Marijuana (SAM), CIVEL, Hillsborough County Anti-Drug Alliance, MMJ International Holdings vs. U.S. government in the D.C. Circuit Court of Appeals
What changed: Plaintiffs filed a new appellate brief seeking to overturn a dismissal and block CMS's hemp-derived products Medicare initiative
Effective / Key date: Government’s opening brief due by November 4
Status: On appeal; lower court dismissed for lack of standing; TRO previously denied; program launched April 1
DMV impact: Medicare beneficiaries and participating providers in DC, Maryland and Virginia could be affected by any court-ordered changes
A new brief has been filed in the lawsuit opposing a federal Medicare initiative that allows participating providers to furnish certain hemp-derived products to beneficiaries within a $500 annual cap. Marijuana Moment reports that Smart Approaches to Marijuana (SAM), Cannabis Industry Victims Educating Litigators (CIVEL), the Hillsborough County Anti-Drug Alliance, and MMJ International Holdings submitted the appellate filing after a federal judge in Washington, D.C. dismissed their case for lack of standing in May. The appeal argues the lower court was wrong and asks the D.C. Circuit to halt or unwind the initiative. Source: Marijuana Moment.
Is Medicare paying for hemp-derived CBD right now?
No. According to federal agencies in the case record, CMS does not directly reimburse for hemp products under the initiative; participating providers may furnish eligible products at their own cost within a $500 cap per beneficiary.
Agencies described the program as a Beneficiary Engagement Incentive (BEI) operating inside existing shared-savings models. The government explained that if a provider’s investment lowers a patient’s total cost of care, the provider and CMS can share savings; if not, the provider absorbs the loss. Agencies emphasized that there is no new federal appropriation or entitlement associated with this program.
Does this new brief stop the program today?
No. The filing itself does not pause the initiative. A prior request to temporarily restrain the program from launching on April 1 was denied, and the case was dismissed in May on standing grounds; it is now on appeal.
In this appeal, plaintiffs challenge the standing ruling and contend the initiative was procedurally flawed and harmful to competitors, providers, and seniors. The government’s opening brief at the D.C. Circuit is due by November 4, and there is no indication in the record that the appellate court has issued an injunction.
What the lawsuit is about
The dispute centers on a CMS initiative—designed after a December executive order from President Donald Trump—that aims to improve access to full-spectrum hemp-derived CBD products for Medicare beneficiaries under specific constraints. Inhalable preparations are excluded. Products may contain no more than 0.3 percent delta-9 THC by dry weight, with up to 3 milligrams of total THC per serving. Opponents argue the initiative is unlawfully adopted and causes concrete harm, while the government maintains plaintiffs have not shown legal injury and that the program fits within shared-savings models without direct product reimbursement.
In the district court, Judge Trevor N. McFadden ruled that none of the plaintiffs established an Article III injury and dismissed the case. He concluded that MMJ International Holdings lacked competitor standing because it does not yet have an approved product on the Medicare market. The new appellate brief counters that MMJ has invested heavily over eight years, holds a DEA Schedule I analytical-lab registration, has Orphan Drug Designation, and has filed INDs—arguing that competitor standing does not require an approved product and that government delay on DEA manufacturing approvals is the main reason MMJ lacks pre-approval market presence.
Legal timeline at a glance
Date | Event | What it means |
|---|---|---|
December (prior year) | Executive order signed | Directed rescheduling rulemaking and improving access to full-spectrum CBD |
April 1 | TRO denied; program launched | No injunction; initiative moved forward |
May | Case dismissed for lack of standing | Plaintiffs appealed the dismissal |
November 4 | Government brief due at D.C. Circuit | Sets the next step in the appeal |
November (this year) | Planned hemp product ban effective date | Could change THC limits; delay sought by CMS director |
How the Medicare hemp initiative works in practice
As described by federal agencies, this is not a broad Medicare Part D or fee-for-service coverage decision for hemp products. Instead, selected providers participating in shared-savings models choose whether to offer eligible hemp-derived products as a beneficiary engagement tool, up to $500 per person per year, and at the provider’s expense. If overall care costs decrease, savings may be shared; if they do not, the provider bears the cost. Separate from this initiative, CMS finalized a rule permitting some hemp products to be offered as specialized, non-primarily health-related benefits through Medicare Advantage plans.
FDA has said it does not intend to interfere with implementation of the Medicare hemp-derived products plan. The White House Office of Management and Budget met this year on an FDA CBD enforcement policy. Meanwhile, Congress members have asked for clarity on whether medical cannabis would be covered by Medicare, which remains an open question outside the scope of this hemp-specific initiative. The lawsuit before the D.C. Circuit focuses on whether the plaintiffs have standing and whether the initiative was properly adopted.
What This Means for Washington DC, Maryland and Virginia Residents
For Medicare beneficiaries in the District of Columbia, Maryland, and Virginia, nothing changes today. The program remains in effect absent an appellate injunction. Beneficiaries do not receive direct Medicare payment for hemp-derived products under this initiative; rather, participating providers may choose to furnish qualifying products within the stated cap. If the plaintiffs ultimately prevail on appeal and the initiative is halted or modified, DC-, Maryland-, and Virginia-based providers participating in the shared-savings models could need to adjust or discontinue furnishing eligible hemp-derived products.
For delivery operators and retailers in the DMV, this is not a green light for Medicare reimbursement or sales. The program’s guardrails explicitly bar inhalable products and limit THC content to no more than 0.3 percent delta-9 by dry weight and up to 3 milligrams total THC per serving. It also relies on participating healthcare providers, not couriers or consumer retail channels. Local rules—such as how DC treats non-medical cannabis activity and how Maryland and Virginia regulate cannabis businesses—operate on separate tracks from this federal Medicare model. If you work in delivery or transport, your compliance obligations under cannabis delivery laws, marijuana delivery regulations, and courier licensing remain governed by your jurisdiction’s rules, not this Medicare initiative.
How This Compares to Other States
This is a federal Medicare initiative, not a state insurance or Medicaid policy, and it is structured as a provider-furnished engagement incentive within federal shared-savings models. State cannabis frameworks—covering licensing, marijuana transport laws, weed delivery compliance, and medical program benefits—continue to function independently. In other words, even if a provider in any state participates in this federal initiative, that does not alter state-level cannabis delivery laws or create a state insurance benefit. For DC and neighboring states, the takeaway is that state law still governs cannabis business licensing and courier regulations while the federal courts evaluate this Medicare-specific approach.
Policy frictions shaping the next moves
Two additional federal crosscurrents matter. First, the executive order that prompted this initiative also pushed the attorney general to finalize marijuana rescheduling, which remains in process. Second, a law signed late last year is scheduled to tighten the federal definition of permissible hemp products this November by prohibiting hemp derivatives with more than 0.4 milligrams of total THC per container. CMS Director Mehmet Oz has urged senators to delay that effective date to preserve access to clinically appropriate full-spectrum CBD for seniors and people with disabilities using Medicare. If the ban proceeds on schedule, it could alter which hemp-derived products qualify under the Medicare initiative’s THC thresholds; if delayed, current parameters could remain longer. The appeal now underway adds another variable: the D.C. Circuit could agree that plaintiffs lack standing or could revive the case for further proceedings.
Bud Lords Take
Analysis: This appeal is fundamentally about standing and administrative process, not about whether CBD helps patients. The court will focus on legal injury, competitor status, and whether CMS stayed within the four corners of its shared-savings models. For DMV readers, the practical question is straightforward: do providers in your area choose to furnish eligible hemp-derived products under the cap, and will they keep doing so if litigation drags on? Because there is no Medicare reimbursement and no inhalables, the initiative’s market impact likely flows through provider purchasing decisions and potential downstream savings calculations—not through retail shelves or delivery menus. Keep an eye on the November 4 government brief and any motions for interim relief; that’s where operational clarity will come from next.
Timeline and Next Steps
Here is what’s scheduled and what to watch for, based solely on the case record and agency communications:
Now: The initiative remains in effect; providers decide whether to furnish eligible products under the $500 cap.
By November 4: The government files its opening brief at the D.C. Circuit.
November (scheduled): A separate federal policy is set to limit hemp derivatives above 0.4 milligrams total THC per container unless delayed by Congress; CMS has advocated for a delay.
After briefs: The D.C. Circuit could set oral argument and later issue a ruling on standing and any merits questions presented.
Action for readers: If you’re a beneficiary, ask your provider whether they participate in the relevant shared-savings model and whether they furnish hemp-derived products under the initiative’s limits. If you’re a provider, review your internal compliance policies against the initiative’s THC thresholds and product exclusions. For delivery and transport operators, continue tracking your state and local licensing and courier rules; this federal program does not change marijuana delivery regulations.
Is inhalable hemp or CBD allowed under the Medicare initiative?
No. Inhalable preparations are not allowed.
What THC limits apply to eligible products?
Products must contain no more than 0.3 percent delta-9 THC by dry weight and up to 3 milligrams of total THC per serving, as described in the case record.
Does Medicare reimburse beneficiaries for these products?
No. Agencies say CMS does not pay for hemp products under the BEI. Participating providers may furnish products at their own cost, within a $500 annual cap per beneficiary.
Could future federal policy change which products qualify?
Yes. A law signed late last year is scheduled to prohibit hemp derivatives with more than 0.4 milligrams total THC per container starting in November, unless delayed. CMS leadership has asked Congress to postpone that effective date.
What is the status of the lawsuit right now?
The district court dismissed the case in May for lack of standing. Plaintiffs appealed and filed a new brief; the government’s opening brief is due by November 4. There is no indication of an injunction as of now.
People also ask: delivery, transport and licensing
We hear these compliance questions often in the DMV market. Here’s how they intersect with this federal case:
Is weed delivery legal in DC? Delivery rules are set locally and are separate from this federal Medicare initiative. Businesses should follow DC-specific courier licensing and transport compliance requirements.
What are cannabis courier licensing rules in Maryland? Maryland sets its own licensing and marijuana transport laws, which this federal initiative does not change.
How do Virginia marijuana delivery regulations apply? Virginia’s regulatory approach is distinct from Medicare policies; delivery operators must comply with Virginia-specific requirements.
Note: The Medicare initiative affects provider decisions in shared-savings models. It does not authorize retail or delivery sales to be reimbursed by Medicare, and it does not supersede any District or state-level cannabis delivery laws.
Attribution and documents
All reported facts in this story are attributed to Marijuana Moment, which covers the appeal, parties, program parameters, and key dates cited by federal agencies and officials.
Have a cannabis story, local update, or strain you want our newsroom to cover? Request a story →
Written by Market Maven AI
Bud Lords AI Cannabis News Writer
Business and finance expert voice. Covers dispensary news, MSO developments, market trends, and financial analysis with industry insight.
Expertise: business · finance
This AI-assisted article was created using the named Bud Lords newsroom personality and reviewed under Bud Lords editorial standards.
Comments